Implementation of Transcranial Magnetic Stimulation for Smoking Cessation
- Disease/Condition
- Smoking
- Drug/Device/Intervention
- Brainsway H4 deep rTMS coil and Brainsway stimulator system
- Study type
- Interventional
- Intervention type
- device
- Primary sponsor
- Centre for Addiction and Mental Health
- Location
- Toronto, Canada
- Phase
- Phase 4
- Start date
- Mar 30, 2024
- End date
- Jun 30, 2025
- Enrollment
- 40 participants
The primary objective of the study is to evaluate the feasibility of implementing rTMS in the Nicotine Dependence Clinic (NDC) at CAMH, in Toronto. This is determine by reach, the extent to which patients are engaging in the rTMS treatment.,Identify rates of adoption of rTMS in Nicotine Dependence Clinic,Identify contextual determinants of rTMS adoption and reach NDC through a qualitative approach.
Repetitive transcranial magnetic stimulation (rTMS) is an alternative non-invasive treatment
 to help people quit smoking. rTMS uses a magnetic field to stimulate regions of the brain
 that are involved in addiction. The two brain regions that are stimulated are the insula and
 the dorsolateral prefrontal cortex, which are involved in drug craving and decision-making,
 respectively.
 
 The goal of this clinical trial is to learn more about the feasibility of offering rTMS as a
 treatment in the Nicotine Dependence Clinic (NDC) to help daily smokers to quit smoking. The
 NDC is at the Center for Addiction and Mental Health (CAMH) at 1025 Queen Street West, in
 Toronto, Canada.
 
 Participants will be asked to come to CAMH to:
 
 - Complete surveys and optional interviews to learn more about their opinions and
 experiences with this treatment
 
 - Start a treatment course that includes 3 weeks of daily (Monday to Friday) rTMS sessions
 followed by 3 weeks of weekly rTMS sessions for a total of 6 weeks. Each session lasts
 about 25 minutes and is provided by an rTMS technician with medical supervision.
 
 Objectives
 
 • Learning about the feasibility of rTMS as a treatment option for patients in the NDC will
 help us improve the treatment when offering it in other clinics, which may help improve
 smoking quit rates and people's overall health.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06346028
- Type
- Device Trial
Access comprehensive clinical trial information for NCT06346028 through Pure Global AI's free database. This Phase 4 trial is sponsored by Centre for Addiction and Mental Health and is currently Recruiting. The study focuses on Smoking. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.